Song Yong Jung
Department of Obstetrics and Gynecology, Pusan National University Yangsan Hospital, Yangsan, South Korea.
Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, South Korea.
Gland Surg. 2021 Mar;10(3):1173-1181. doi: 10.21037/gs-2019-ursoc-08.
The mainstay management of advanced ovarian cancer is maximal cytoreductive surgery followed by chemotherapy. Neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) are alternative treatments for patients with comorbidity, poor performance status, and predicted for suboptimal debulking surgery. It is the invariable principle in any situation that no residual disease after the completion of surgery is useful for patients with ovarian cancer. Therefore, the prediction of optimal debulking before the treatment of ovarian cancer is of utmost importance. Many studies have reported on the use of serum biomarkers, such as cancer antigen 125 (CA125) or human epididymis 4 (HE4), and imaging studies, such as computed tomography (CT), diffusion-weighted magnetic resonance imaging (DW-MRI), and positron emission tomography (PET)/CT, to identify adequate surgical candidates for primary debulking surgery (PDS). Laparoscopy has also been studied as a reliable tool for the prediction of optimal debulking. Here, we summarize a review of the related literature.
晚期卵巢癌的主要治疗方法是最大限度的细胞减灭术，随后进行化疗。新辅助化疗（NACT）和间隔减瘤手术（IDS）是合并症、身体状况差且预计无法进行理想减瘤手术的患者的替代治疗方法。对于卵巢癌患者，无论在何种情况下，手术完成后无残留病灶都是不变的原则。因此，在卵巢癌治疗前预测理想减瘤情况至关重要。许多研究报告了使用血清生物标志物，如癌抗原125（CA125）或人附睾蛋白4（HE4），以及影像学检查，如计算机断层扫描（CT）、扩散加权磁共振成像（DW-MRI）和正电子发射断层扫描（PET）/CT，来识别适合进行初次减瘤手术（PDS）的手术候选人。腹腔镜检查也已被研究作为预测理想减瘤的可靠工具。在此，我们总结了相关文献综述。
